Search
for
Sort by
Research 31–60 of 334
- Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
- Exploring the Role of GLP‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
- 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- Ann Robinson’s research reviews —12 May 2022
- Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
- Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
- INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- Farmácia Avenida Brasil, Porto
- Debatable Topics in PCOS Patients
- Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Understanding Polycystic Ovary Syndrome
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
- Anti-androgen therapy in polyendocrine metabolic ovary syndrome (PMOS, formerly PCOS): efficacy, safety, and phenotype-oriented clinical decision-making
- Skin as a Metabolic Organ: Dermatologic Markers of Morbid Obesity and Their Role in Risk Stratification and Treatment Monitoring
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
- The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review
- Mechanisms of Impaired Skeletal Muscle Regeneration and Therapeutic Approaches in Aging and Chronic Disease
- Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study